To elucidate the relationship between genetic alterations and the sensitivity of glioma cell lines to the novel compounds ZOT5-1-Me and ZOT5-1-Et, we analysed the mutation status of key biomarkers, including TP53, PTEN, CDKN2A, and IDH, across seven glioma cell lines: SF-268, SNB-19, SNB-75, U251, SF-539, SF-295, and U-87 MG (Table 2). This evidence concerns the gene CDKN2A and glioma.